Form 4: Inozyme Pharma COO Matthew Winton Reports Acquisition of Common Stock

Inozyme Pharma's COO, Matthew Winton, reports acquiring 3,188 shares of common stock through the company's Employee Stock Purchase Plan.

Summary

• On March 28, 2024, Matthew Winton, the COO of Inozyme Pharma, Inc. (INZY), acquired 3,188 shares of common stock.
• The acquisition was made through the company's 2020 Employee Stock Purchase Plan (ESPP).
• The shares were purchased at $3.33 per share.
• This purchase was for the ESPP purchase period of October 1, 2023, through March 31, 2024.
• The purchase price was 85% of the closing price of Inozyme Pharma's common stock on October 2, 2023, the first trading day of the purchase period.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock acquisition by an executive, indicating neither significant positive nor negative implications.

Positives

• The COO's participation in the ESPP demonstrates confidence in the company's future.

Industry Context

Form 4 filings are standard practice and provide transparency into insider transactions, allowing investors to monitor the actions of company executives and their confidence in the company's stock.

Stakeholder Impact

• The stock purchase by a key executive could be viewed positively by shareholders, signaling confidence in the company's prospects.

Key Dates